Guideline-Driven PGx Testing: A new, targeted testing approach covering all AMP Tier 1 and Tier 2 pharmacogenomic recommendations.

Dr. Jai Patel, Associate VP, Translational Research, Director, Cancer Pharmacology & Pharmacogenomics, Atrium Health Levine Cancer, and Dr. Vicky Pratt, past president of AMP, have been at the forefront of pharmacogenomics, continually keeping pace with the evolving PGx landscape to implementing relevant, guideline-driven testing.

In this workshop they will discuss the validation and implementation of the new VeriDose Core v2.0 PGx Panel, which contains all AMP Tier 1 and Tier 2 consensus recommendations for standardization of alleles for clinical pharmacogenomic genotyping assays for CYP2C19, CYP2C9, warfarin genes, CPY2D6, CYP3A4, CYP3A5, TPMT and NUDT15. Attendees will gain insights into these evidence-based guidelines and the implementation of standardized PGx testing within the laboratory.